Form 4: Amgen EVP Acquires 12,063 Shares

Amgen's EVP & Chief Technology Officer, David M. Reese, acquired 12,063 shares of common stock on March 3, 2026, increasing his beneficial ownership to 47,650 shares.

Summary

• David M. Reese, EVP & Chief Technology Officer of Amgen Inc., acquired 12,063 shares of Amgen common stock.
• The transaction occurred on March 3, 2026, with an acquisition price of $0 per share, indicating a grant or award.
• Following this acquisition, Mr. Reese beneficially owns a total of 47,650 shares of Amgen common stock.
• The shares include 667 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are credited to unvested Restricted Stock Units (RSUs) and paid out in shares on a one-to-one basis according to the vesting schedule.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it represents an executive increasing their stake in the company, aligning their interests with shareholders, though it's a routine compensation event rather than an open market purchase.

Positives

• A senior executive, David M. Reese, acquired 12,063 shares of company stock, which can signal confidence in the company's future prospects.
• The acquisition was at a price of $0, suggesting these were likely part of an equity compensation plan, aligning executive incentives with shareholder interests.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider acquisitions, especially by high-ranking executives like an EVP & Chief Technology Officer, are often viewed positively by the market as they suggest management's belief in the company's long-term value. This is a routine disclosure for executive compensation.

Comparison to Industry Standards

• Executive equity grants are a standard practice across the biotechnology and pharmaceutical industries, aligning executive incentives with shareholder returns.
• Companies like Pfizer (PFE), Merck (MRK), and Johnson & Johnson (JNJ) also utilize similar equity incentive plans for their senior leadership, often involving Restricted Stock Units (RSUs) and Dividend Equivalents (DEs).
• The structure of the grant, including DEs, is consistent with common compensation practices designed to reward long-term performance and retention.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to equity ownership.
• Employees: Reinforces the company's commitment to executive compensation plans that incentivize long-term performance.

Next Steps

• Continued vesting of the acquired shares and Dividend Equivalents according to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.

Key Dates

Recommendation

The acquisition of shares by a key executive, while positive for aligning interests, is a routine compensation event and does not provide sufficient new information to alter a fundamental investment thesis. It reinforces a 'hold' stance, indicating stability in executive commitment.

Keywords

Amgen, AMGN, Insider Trading, Form 4, Stock Acquisition, Executive Compensation, David M. Reese, Common Stock, Equity Incentive Plan, Restricted Stock Units